DaVita (NYSE:DVA) Cut to “Buy” at StockNews.com

StockNews.com cut shares of DaVita (NYSE:DVA) from a strong-buy rating to a buy rating in a research report report published on Monday.

A number of other equities research analysts have also issued reports on DVA. UBS Group upped their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a buy rating in a report on Wednesday, February 14th. Barclays upped their price target on DaVita from $133.00 to $150.00 and gave the stock an equal weight rating in a research note on Monday. TheStreet upgraded DaVita from a c+ rating to a b- rating in a report on Wednesday, February 7th. Finally, Truist Financial raised their target price on DaVita from $130.00 to $135.00 and gave the stock a hold rating in a research report on Tuesday, February 20th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $121.33.

DaVita Trading Down 1.3 %

NYSE DVA opened at $135.84 on Monday. The company has a 50 day moving average price of $134.33 and a 200 day moving average price of $114.05. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. DaVita has a 52 week low of $71.51 and a 52 week high of $145.04. The firm has a market cap of $11.91 billion, a PE ratio of 15.44, a price-to-earnings-growth ratio of 1.17 and a beta of 1.04.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.43. The company had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. DaVita’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. As a group, sell-side analysts forecast that DaVita will post 9.49 EPS for the current fiscal year.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider James O. Hearty sold 26,164 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the transaction, the insider now owns 20,264 shares of the company’s stock, valued at approximately $2,424,384.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 11,285 shares of DaVita stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the transaction, the insider now directly owns 81,297 shares in the company, valued at $9,814,986.81. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock worth $16,551,071 in the last three months. Insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On DaVita

Several large investors have recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. lifted its holdings in DaVita by 175.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 50,343 shares of the company’s stock worth $4,759,000 after acquiring an additional 32,062 shares during the last quarter. IFM Investors Pty Ltd boosted its position in shares of DaVita by 78.1% in the 3rd quarter. IFM Investors Pty Ltd now owns 21,115 shares of the company’s stock valued at $1,996,000 after purchasing an additional 9,261 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of DaVita by 19.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,369 shares of the company’s stock worth $1,642,000 after buying an additional 2,790 shares during the period. Park Avenue Securities LLC acquired a new position in shares of DaVita in the third quarter worth $332,000. Finally, CENTRAL TRUST Co grew its stake in shares of DaVita by 93.3% in the 3rd quarter. CENTRAL TRUST Co now owns 1,448 shares of the company’s stock valued at $137,000 after buying an additional 699 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.